CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Anteris Technologies Global Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Anteris Technologies Global Corp
860 Blue Gentian Road, Suite 340
Phone: (651) 493-0606p:651 493-0606 EAGAN, MN  55121  United States Ticker: AVRAVR

Business Summary
Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. It is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board JohnSeaberg 73 3/1/2017 3/1/2017
Chief Executive Officer, Managing Director, Director Wayne G.Paterson 58 3/1/2017
Chief Financial Officer MatthewMcdonnell 52 11/1/2018 11/1/2018
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Admedus (Australia) Pty Ltd
Admedus Biomanufacturing Pty Ltd
Anteris Aus Operations Pty Ltd
5 additional Business Names available in full report.

General Information
Number of Employees: 138 (As of 10/31/2024)
Outstanding Shares: 35,939,816 (As of 9/30/2024)
Stock Exchange: NASD
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 21, 2024